International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 5 , Pages 1253-1257 , 1 August 2001

Five-year biochemical outcome after prostate brachytherapy for hormone-naive men ≤ 62 years of age

  • Gregory S Merrick, M.D.

      Affiliations

    • Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV, USA
    • The George Washington University Medical Center, Division of Radiation Oncology and Biophysics, Washington, DC, USA
    • Corresponding Author InformationReprint requests to: Dr. Gregory S. Merrick, Schiffler Cancer Center, Wheeling Hospital, 1 Medical Park, Wheeling, WV 26003-6300
    • ,
  • Wayne M Butler, Ph.D.

      Affiliations

    • Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV, USA
    • ,
  • Jonathan H Lief, Ph.D.

      Affiliations

    • Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV, USA
    • Wheeling Jesuit University, Wheeling, WV, USA
    • ,
  • Robert W Galbreath, Ph.D.

      Affiliations

    • Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV, USA
    • Wheeling Jesuit University, Wheeling, WV, USA

,Accepted 21 February 2001.

References 

  1. Merrick GS, Butler WM, Lief JH, et al.  Is brachytherapy comparable with radical prostatectomy and external beam radiation for clinically localized prostate cancer?. Tech Urol. 2001;7:12–19
  2. Blasko JC, Grimm PD, Sylvester JE, et al.  Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839–850
  3. Ragde H, Korb LJ, Elgamal AA, et al.  Modern prostate brachytherapy (Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up). Cancer. 2000;89:135–141
  4. Critz FA, Williams WH, Levinson AK, et al.  Simultaneous irradiation for prostate cancer (Intermediate results with modern techniques). J Urol. 2000;164:738–743
  5. Blasko JC, Wallner K, Grimm PD, et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol. 1995;154:1096–1099
  6. Dattoli M, Wallner K, True L, et al.  Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys. 1999;45:853–856
  7. Zelefsky MJ, Hollister T, Raben A, et al.  Five-year biochemical outcome, and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47:1261–1266
  8. Merrick GS, Butler WM, Lief JH, et al. Five-year biochemical outcome following permanent interstitial brachytherapy for T1–T3 prostate cancer. Int J Radiat Oncol Biol Phys In press.
  9. Harlan L, Brawley O, Pommerenke F, et al.  Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995;13:93–100
  10. American Society for Therapeutic Radiology, and Oncology Consensus Panel . Consensus Statement (Guidelines for PSA following radiation therapy). Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  11. Fleming ID, Cooper JS, Henson DE, et al.  AJCC Cancer Staging Handbook. 5th ed.. Philadelphia: Lippincott-Raven Press; 1998;
  12. Merrick GS, Butler WM, Farthing WH, et al.  The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection. J Brachytherapy Int. 1998;14:113–121
  13. Nath R, Anderson LL, Luxton G, et al.  Dosimetry of interstitial brachytherapy sources (Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43). Med Phys. 1995;22:209–234
  14. Butler WM, Merrick GS, Lief JH, et al.  Comparison of seed loading approaches in prostate brachytherapy. Med Phys. 2000;27:381–392
  15. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy (Rationale, design, and evaluation). Tech Urol. 2000;6:78–84
  16. Merrick GS, Butler WM, Dorsey AT, et al.  Potential role of various dosimetric quality indicators in prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;44:717–724
  17. Merrick GS, Butler WM, Dorsey AT, et al.  Rectal dosimetric analysis following prostatic conformal brachytherapy. Int J Radiat Oncol Biol Phys. 1999;43:1021–1027
  18. Merrick GS, Butler WM, Dorsey AT, et al.  The influence of timing on the dosimetric analysis of transperineal ultrasound guided prostatic conformal brachytherapy. Radiat Oncol Invest. 1998;6:182–190
  19. Merrick GS, Butler WM, Dorsey AT, et al. The effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation. Tech Urol In press.
  20. Merrick GS, Butler WM, Dorsey AT, et al.  The influence of prophylactic dexamethasone on edema following prostate brachytherapy. Tech Urol. 2000;6:117–122
  21. Butler WM, Dorsey AT, Nelson KR, et al.  Quality assurance calibration of I-125 rapid strand in a sterile environment. Int J Radiat Oncol Biol Phys. 1998;41:217–222
  22. Merrick GS, Butler WM, Dorsey AT, et al.  Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys. 2000;46:215–220
  23. Richie JP, Catalona WJ, Ahmann FR, et al.  Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urol. 1993;42:365–374
  24. Carter HB, Epstein JI, Partin AW. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urol. 1999;53:126–130
  25. Catalona WJ, Smith D. Five-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994;152:1837–1842
  26. Herold DM, Hanlon AL, Movsas B, et al.  Age related prostate cancer metastases. Urology. 1998;51:985–990
  27. Catalona WJ, Smith D. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer (Intermediate-term results). J Urol. 1998;160:2428–2434
  28. Freedman GM, Hanlon AL, Lee WR, et al.  Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation. Int J Radiat Oncol Biol Phys. 1996;35:243–250
  29. Pound CR, Partin AW, Epstein JI, et al.  Prostate-specific antigen after anatomic radical retropubic prostatectomy (Patterns of recurrence and cancer control). Urol Clin NA. 1997;24:395–406
  30. Zelefsky MJ, Leibel SA, Gaudin PB, et al.  Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  31. Hanlon AL, Hanks GE. Failure patterns and hazard rates for failure suggest the cure of prostate cancer by external beam radiation. Urol. 2000;55:725–729
  32. Valicenti R, Lu J, Pilepich M, et al.  Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol. 2000;18:2740–2746

PII: S0360-3016(01)01539-5

International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 5 , Pages 1253-1257 , 1 August 2001

Article Tools

* Image Usage & Resolution